证券代码：300261 证券简称：雅本化学 公告编号：2025-048 雅本化学股份有限公司 第六届董事会第四次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司(以下简称"公司"司第六届董事会第四次（临时）会议于 2025 年 6 月 16 日上午 10:00 以现场结合通讯方式召开，会议通知已于 2025 年 6 月 11 日以邮件方式送达全体董事和监事。本次会议应出席董事 8 名，实际出席会议董 事 8 名。会议由公司董事长兼总经理蔡彤先生主持，公司部分监事及高级管理人员 列席了会议。本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 一、审议通过了《关于修订<公司章程>的议案》 根据《上市公司章程指引》《深圳证券交易所创业板股票上市规则》等最新法律 法规、规范性文件的要求，结合实际经营情况，董事会同意对《公司章程》进行修 订。详见中国证监会指定信息披露网站刊登的公告。 表决结果：赞成8票，反对0票，弃权0票。 本议案需提 ...

Group 1: Business Operations - The company has a production capacity of 2,000 tons/year for chlorantraniliprole intermediates, utilizing a CDMO business model to provide customized production based on customer orders [1] - The company currently supplies this product exclusively to a single customer and is in discussions regarding the renewal of the cooperation agreement, which has not yet been formally signed [1][2] - The company’s chlorantraniliprole intermediates business has not been negatively impacted by the "Shandong Youdao incident" as it does not participate in market competition [1][2] Group 2: Agricultural Business Development - The agricultural business is implementing a "key customer strategy" and transitioning from a focus on a single major product to multiple innovative products [3] - The company is actively developing several innovative pesticide projects across its production bases in Lanzhou and Yancheng, which are at various stages of project initiation, construction, and capacity ramp-up [3][4] - The company has established collaborations with several leading innovative pesticide companies to provide high-quality CDMO services and products [4] Group 3: International Trade and Risk Management - The company prioritizes responding to CDMO business customer needs, with many key clients transferring cooperation opportunities to domestic bases in China [5][6] - The company maintains a strong risk management capability due to its multinational client base, which allows for flexible supply chain management [5][6] Group 4: Pharmaceutical Business Development - The company has increased investment in pharmaceutical R&D and production facilities, enhancing the overall competitiveness of its supply chain [7] - The Lanzhou base has established four subsidiaries focused on innovative pesticide and pharmaceutical intermediates, with some products already in production [8] Group 5: Health and Biotechnology - The company is developing a health business leveraging its expertise in organic chemistry and biotechnology, with several health products already available on cross-border e-commerce platforms [9] - The integration of biochemistry and continuous flow technology is expected to enhance the company's competitiveness in synthetic biology and green chemistry [10]

Group 1 - The agricultural pesticide sector continues its strong performance, with Changqing Co., Ltd. achieving a two-day consecutive limit-up [1] - Guangkang Biochemical surged over 15%, reaching a new historical high, while Lianhua Technology approached the limit-up [1] - Other companies such as Nuobixin, Yabenn Chemical, Hailier, and Huillong also experienced gains [1] Group 2 - On June 5, ST Hongtaiyang announced a price adjustment for its 97% chlorantraniliprole product, raising the price to 300,000 yuan per ton, with limited supply [1] - This price increase represents a more than 40% rise compared to the market's low point of 210,000 yuan per ton last year [1]

Group 1: Business Operations - The company has an annual production capacity of 2,000 tons for chlorantraniliprole intermediates, operating under a CDMO model, which allows for customized production based on client orders [1] - The chlorantraniliprole business is currently not affected by the "Shandong Youdao" incident, as the company has not participated in market competition and adjusts supply based on client demand [1] - The company has not yet signed a new cooperation agreement after the expiration of a long-term contract, but normal supply to clients continues, with intentions for extension being discussed [2] Group 2: Impact of Tariff Policies - The company’s CDMO business model has fostered closer relationships with clients, allowing for transparent communication, which helped mitigate the impact of a 10% tariff increase in the U.S. [3] - Clients, primarily multinational corporations, have the flexibility to shift procurement needs to domestic factories or other countries with lower tariffs, enhancing resilience against tariff changes [3] Group 3: Agricultural Business Development - The agricultural business is focused on a "big client strategy" and CDMO model, with several projects at various stages of development, expected to improve performance as products are launched [4] Group 4: Pharmaceutical Business Development - The company is increasing investment in pharmaceutical R&D and production facilities, aiming to strengthen the integration of its pharmaceutical sector and enhance supply chain competitiveness [5][6] Group 5: Environmental Business Development - The subsidiary engaged in kitchen waste treatment has seen slowed growth due to market changes, but plans to pivot towards biomass waste resource management to improve overall business performance [6]

一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届董 事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议通 过了《关于公司为子公司提供担保及子公司互相担保的议案》，为满足子公司 的经营发展需要，公司同意为甘肃兰沃科技有限公司（以下简称"兰沃科技"） 办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮 资讯网上披露的《关于公司为子公司提供担保及子公司互相担保的公告》（公 告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股东大会审 议通过了上述议案。 二、担保的进展情况 证券代码：300261 证券简称：雅本化学 公告编号：2025-047 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 公司名称：甘肃兰沃科技有限公司 注册资本：10,000万元 法定代表人：施宏伟 成立日期：2020年6月29日 经营期限：自2020年6月29日至2040年6月28日 公司住所：甘肃省兰州市兰州新 ...

Market Performance - The NMN concept index rose by 2.72%, ranking fourth among concept sectors, with 24 stocks increasing in value [1][2] - Notable gainers included Xiwang Food, ST Hongtai, and Yabao Chemical, which saw increases of 12.41%, 5.23%, and 4.44% respectively [1][2] - Decliners included Zhongsheng Pharmaceutical and Kanghui Pharmaceutical, which fell by 2.41% and 0.36% respectively [1][2] Capital Flow - The NMN concept sector experienced a net inflow of 284 million yuan, with 15 stocks receiving net inflows [2][3] - Xiwang Food led the net inflow with 130 million yuan, followed by Zhejiang Medicine and Yabao Chemical with net inflows of 59.73 million yuan and 51.62 million yuan respectively [2][3] Stock Performance - Xiwang Food had a net inflow rate of 43.86%, while ST Hongtai and Yabao Chemical had rates of 10.26% and 7.79% respectively [3][4] - Other notable stocks included Youa Shares and Hanyu Pharmaceutical, with net inflow rates of 6.93% and 5.31% respectively [3][4] - Decliners in the sector included Zhongsheng Pharmaceutical with a net outflow of 69.36 million yuan and a decline of 2.41% [4]

证券代码：300261 证券简称：雅本化学 公告编号：2025-046 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》，为满足子公 司的经营发展需要，公司同意为兰州雅本精细化工有限公司（以下简称"兰雅 精化"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相担保的公 告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股 东大会审议通过了上述议案。 二、担保的进展情况 鉴于招商银行股份有限公司兰州分行（以下简称"招行银行兰州分行"） 前次向兰雅精化提供的授信额度人民币 1,000 万元即将到期，为满足日常经营 发展需要，公司近日与招行银行兰州分行续签了《最高额 ...

Core Viewpoint - Yabao Chemical (雅本化学) is navigating through a challenging industry cycle but shows signs of recovery with significant revenue growth in Q1 2025 and a substantial reduction in losses, driven by technological innovation and capacity optimization [1][4]. Group 1: Company Performance - In 2024, Yabao Chemical's performance was negatively impacted by industry downturns, market competition, and asset impairment, leading to an overall poor performance [1]. - The company reported a 43.52% year-on-year increase in revenue for Q1 2025, with losses narrowing by over 70%, indicating a recovery signal [1]. - The company’s R&D investment reached 123 million yuan in 2024, accounting for approximately 10% of total revenue [2]. Group 2: Technological Innovation - Yabao Chemical emphasizes the importance of technological innovation as a driving force for the CDMO industry, particularly in areas like continuous manufacturing and biocatalysis [2]. - The company has a total of 237 patents, including 122 invention patents, with a focus on biocatalysis and continuous flow tubular reactions [2]. - The company has successfully published articles in renowned journals, showcasing its research and development capabilities [3]. Group 3: Strategic Focus - The company is committed to a dual development strategy in innovative pesticides and pharmaceuticals, enhancing its integration into global supply chains [3]. - Future plans include optimizing core business areas, accelerating capacity transformation at various bases, and deepening collaborations with major clients [4]. - Yabao Chemical aims to strengthen cost control and supply chain resilience while enhancing sustainable development through ESG initiatives [4].

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20250515 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | | --- | --- | --- | | 类别 | √ 业绩说明会 □ 媒体采访 | | | | □ 新闻发布会 □ 路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 年 月 日（周四）下午 2025 15 15:00~17:00 | 5 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | | 用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事长、总经理蔡彤 | | | 员姓名 | 2、董事、副总经理王卓颖 | | | | 3、财务总监王爱军 | | | | 4、董事会秘书、副总经理王一川 | | | | 5、独立董事饶艳超 | | | | 投资者提出的问题及公司回复情况 | | | | 1、请问公司将何时与富美实签约？ ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-045 雅本化学股份有限公司 2024 年年度股东大会决议公告 特别提示： 1、本次股东大会无增加、变更、否决议案的情况。 2、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 雅本化学股份有限公司（以下简称"公司"）2024 年年度股东大会（以下 简称"股东大会"）现场会议于 2025 年 5 月 13 日下午 14:30 在上海市浦东新区 李冰路 67 弄 4 号雅本张江创新中心召开；同时使用深圳证券交易所交易系统网 络投票于 2025 年 5 月 13 日交易时间接受网络投票，即 9:15-9:25，9:30-11:30 和 13:00-15:00；使用深圳证券交易所互联网投票系统于 2025 年 5 月 13 日上午 9:15 至下午 15:00 期间接受网络投票。 出席本次股东大会的股东及股东的委托代理人共计 302 人，代表有表决权的 股份数为 275,251,895 股，占公司股份总数的 28.5736％。其中，参加现场会议的 股东及股东代表 4 人，代表股份 265,398,089 股，占公司股份总数的 ...